🔗 Share this article

While the US undertakes sweeping adjustments to its vaccine recommendations, one figure has emerged somewhat surprisingly: Høeg, an American of Danish descent physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots during the global health crisis and has focused upon potential fatalities following COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Immunization Schedule

Public health authorities were set to announce radical revisions to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s immunization schedule, it is understood – a substantial departure that would put the US out of alignment with a large portion of the global community with little proof for public health gain. The announcement has been delayed until the next year.

In place of the director of the vaccine center, Høeg is listed to speak at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to run the division this year.

Consolidating Power at the Agency

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad solidify control at the FDA – and it points to a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric shot schedules in the US so as to align more in line with the Danish model, a society with nationalized medicine and a citizenry approximately the population of Wisconsin’s.

So far comments, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Expertise

The appointee has no apparent experience in medication creation, approval processes or administrative roles, which has been customary for previous directors of the CBER. She has served at the FDA as a key advisor to the agency head and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for overseeing the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a large organization. She has no expertise in industry regulation.”

Former commissioners of CBER would “understand legal statutes and the science of drug development”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that former directors who ran the center have had.”

The drug center has an vast portfolio at the FDA, the former commissioner emphasized.

“Everybody just focuses on the new drug program, but the generic program clears numerous off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and more, and all of those must be looked after,” she explained. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative element to the job, which supervises in excess of 5,000 employees. “It is a huge administrative position, if you do it right,” she added.

Agency Reaction and Controversial Policies

In response to questions about Dr. Høeg's credentials and whether this assignment indicates increased cooperation among agency officials on vaccines, a representative stated that the “inquiries rely on inaccurate premises”.

“Her experience aligns with the functions of her position,” the official said, pointing to the period Dr. Høeg spent advising the agency head on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's controversial expedited review system, a contentious expedited drug-approval program that apparently troubled her preceding directors. “By what process are these drugs being chosen for this expedited pathway? Who is making the decisions?” Dr. Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards less stringent oversight of pharmaceuticals, aside from shots.”

Public Past Work on Immunizations

With immunizations, Høeg has a clearer, if troubling, track record, Howard said. She authored a study using non-validated public submissions to determine the frequency of myocarditis after COVID-19 vaccination. She advised the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are pose a greater threat than they are.

Included in her “desired changes” for the new government featured altering rules for novel immunizations and ending “optional” immunizations, she stated post-election on a online show. At the FDA, Dr. Høeg has allegedly suggested preventing adolescent males from getting Covid vaccines.

“She’s an thorough true believer who begins with her preconceived notions and reverse-engineers to fit the data in a highly disingenuous, untruthful fashion,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|